Published in BMC Fam Pract on November 05, 2010
Duloxetine use in chronic painful conditions--individual patient data responder analysis. Eur J Pain (2013) 0.88
A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract (2013) 0.88
Management continuity in local health networks. Int J Integr Care (2012) 0.85
Ion channels as drug targets in central nervous system disorders. Curr Med Chem (2013) 0.84
Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf (2014) 0.82
Options for treating postherpetic neuralgia in the medically complicated patient. Ther Clin Risk Manag (2013) 0.81
Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting. Clin Drug Investig (2013) 0.79
Peripheral edema with pregabalin. CMAJ (2012) 0.78
Pharmacological management of chronic low back pain in older patients: a randomized controlled trial of the effect of pregabalin and opioid administration. Eur Spine J (2015) 0.76
Comparison of oral absorption models for pregabalin: usefulness of transit compartment model. Drug Des Devel Ther (2016) 0.75
A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D (2016) 0.75
Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia. Clinicoecon Outcomes Res (2013) 0.75
Activation of Antioxidative Functions by Radon Inhalation Enhances the Mitigation Effects of Pregabalin on Chronic Constriction Injury-Induced Neuropathic Pain in Mice. Oxid Med Cell Longev (2015) 0.75
Low doses of amitriptyline, pregabalin, and gabapentin are preferred for management of neuropathic pain in India: is there a need for revisiting dosing recommendations? Korean J Pain (2017) 0.75
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Controlling the risk of spurious findings from meta-regression. Stat Med (2004) 6.80
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology (2003) 3.45
EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol (2006) 2.86
Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev (2009) 2.83
A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol (2002) 2.57
Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med (2002) 2.49
Treatment of neuropathic pain: an overview of recent guidelines. Am J Med (2009) 2.43
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology (2004) 2.40
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain (2004) 2.32
Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol (2008) 2.11
Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain (2005) 1.97
The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain (2006) 1.82
Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin (2006) 1.72
Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev (2009) 1.56
Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain (2007) 1.49
"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews. Pain (2010) 1.31
Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf (2007) 1.20
Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol (2008) 1.11
Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol (2003) 1.11
Painful neuropathic disorders: an analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manag (2007) 1.07
Pharmacological management of persistent pain in older persons. Pain Med (2009) 1.05
Pregabalin for neuropathic pain based on recent clinical trials. Curr Pain Headache Rep (2006) 0.99
Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract (2007) 0.92
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. Cephalalgia (2009) 0.91
A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther (2007) 0.91
Pharmacological treatment of neuropathic pain in older persons. Clin Interv Aging (2008) 0.90
Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother (2004) 0.88
Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain (2007) 0.82
Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care (2010) 0.80
Pharmacological management of neuropathic pain in older adults: an update on peripherally and centrally acting agents. J Pain Symptom Manage (2009) 0.78
Use of pregabalin in patients with painful neuropathic disorders under the care of general practitioners in the U.K. Pain Pract (2008) 0.77
Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care (2008) 2.47
The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology (2007) 2.46
Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol (2010) 2.32
Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol (2007) 1.94
Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol (2009) 1.88
Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc (2003) 1.83
The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain (2010) 1.81
Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr (2002) 1.73
Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain (2011) 1.50
Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol (2003) 1.43
Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics (2008) 1.20
The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes (2011) 1.19
Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol (2007) 1.18
Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Appl Health Econ Health Policy (2011) 1.05
Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon Outcomes Res (2013) 1.01
The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. J Manag Care Pharm (2012) 1.01
Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis. BMC Musculoskelet Disord (2010) 0.94
Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ (2011) 0.93
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther (2013) 0.93
Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care (2010) 0.92
Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med (2008) 0.92
Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales. Health Qual Life Outcomes (2009) 0.92
Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: a double-blind, randomized, parallel-group study. Clin Ther (2007) 0.91
Treatment patterns among physician specialties in the management of fibromyalgia: results of a cross-sectional study in the United States. Curr Med Res Opin (2011) 0.91
The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci (2013) 0.90
Central amplification and fibromyalgia: disorder of pain processing. J Neurosci Res (2011) 0.89
Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord (2009) 0.88
The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin (2010) 0.88
Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr Med Res Opin (2008) 0.88
A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract (2013) 0.88
Reduction in opioid-related adverse events and improvement in function with parecoxib followed by valdecoxib treatment after non-cardiac surgery: a randomized, double-blind, placebo-controlled, parallel-group trial. Clin Drug Investig (2009) 0.87
Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol (2008) 0.87
Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. Am J Ther (2010) 0.87
Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract (2009) 0.86
Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry (2010) 0.86
Identifying fibromyalgia-associated symptoms and conditions from a clinical perspective: a step toward evaluating healthcare resource utilization in fibromyalgia. Pain Pract (2010) 0.86
Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. J Med Econ (2011) 0.84
Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin (2010) 0.84
Designing a new proof-of-principle trial for treatment of partial seizures to demonstrate efficacy with minimal sample size and duration-a case study. Epilepsy Res (2013) 0.83
Time to improvement of pain and sleep quality in clinical trials of pregabalin for the treatment of fibromyalgia. Pain Med (2014) 0.83
Pain responder analysis: use of area under the curve to enhance interpretation of clinical trial results. Pain Pract (2009) 0.83
Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Anesth Analg (2009) 0.82
The meaning of pain relief in a clinical trial. J Pain (2005) 0.82
Mortality associated with gastrointestinal bleeding events: Comparing short-term clinical outcomes of patients hospitalized for upper GI bleeding and acute myocardial infarction in a US managed care setting. Clin Exp Gastroenterol (2009) 0.82
Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther (2012) 0.82
Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. Curr Med Res Opin (2013) 0.82
Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract (2011) 0.81
The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J Med Econ (2012) 0.81
Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials. Epilepsia (2010) 0.81
Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains. BMC Musculoskelet Disord (2012) 0.81
Toward characterization and definition of fibromyalgia severity. BMC Musculoskelet Disord (2010) 0.81
Tracking low back problems in a major self-insured workforce: toward improvement in the patient's journey. J Occup Environ Med (2014) 0.81
Simplifying Fibromyalgia Assessment: The VASFIQ Brief Symptom Scale. Ther Adv Musculoskelet Dis (2011) 0.81
Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med (2011) 0.81
Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care (2010) 0.80
Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin (2012) 0.80
An open-label, add-on study of pregabalin in patients with partial seizures: a multicenter trial in Greece. Seizure (2011) 0.79
Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain. Health Qual Life Outcomes (2011) 0.78
Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study. BMC Ophthalmol (2010) 0.78
Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract (2010) 0.78
Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin. Clin J Pain (2012) 0.77
Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Am J Ther (2015) 0.77
Further qualification of a therapeutic responder index for patients with chronic low back pain. J Rheumatol (2010) 0.77
Applying area-under-the-curve analysis to enhance interpretation of response profiles: an application to sleep quality scores in patients with fibromyalgia. Qual Life Res (2010) 0.76
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. J Med Econ (2009) 0.76
Sensory pain qualities in neuropathic pain. J Pain (2011) 0.76
Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia. Pain Med (2013) 0.76
Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J (2010) 0.75
Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. J Ophthalmol (2010) 0.75
Celecoxib. J R Soc Med (2006) 0.75
Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia. Clin J Pain (2016) 0.75
Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials. Curr Med Res Opin (2011) 0.75
Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin. J Med Econ (2012) 0.75
Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin (2013) 0.75